Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Noorik Biopharmaceuticals AG
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
27Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06256432CT.gov Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatorenal Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ambrisentan (this asset) | Noorik Biopharmaceuticals AG | P2 | CC · 42 |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | Noorik Biopharmaceuticals AG | P4 | A |
| Normal Human Serum Albumin | Massachusetts General Hospital | P4 | BBB |
| Norfloxacin | Hospital Clinic of Barcelona | P4 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | University of California, Los Angeles | P2/3 | BB |
| Midodrine | University of California, Los Angeles | P2/3 | BB |
| [Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin | Ocelot Bio, Inc | P2 | B |
| Angiotensin Ii | University of California, Los Angeles | P2 | CCC |
| Pentoxyfylline | Patrick Northup, MD | N/A | D |
+2 more in the Hepatorenal Syndrome cohort
Other indications for Ambrisentan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pulmonary Hypertension | — | P4 | CCC · 53 |
| Cirrhosis Of Liver | — | P4 | CCC · 52 |
| Idiopathic Pulmonary Fibrosis | — | P3 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)Noorik Biopharmaceuticals AGA
- Normal Human Serum AlbuminMassachusetts General HospitalBBB
- NorfloxacinHospital Clinic of BarcelonaBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-University of California, Los AngelesBB
- MidodrineUniversity of California, Los AngelesBB
Citation
Floatz Terminal. Ambrisentan in Hepatorenal Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ambrisentan-hepatorenal-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →